RxDoctor Payments Data

Peter White, MD

Pulmonary Disease · Springfield, ILNPI 1659313823

Payments from drug & device makers

$20,285in general payments, 2019–2025

Across 49 payments — averaging $413.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$20K
  • GSK$194
  • Zimmer Biomet$95
  • Inspire Medical Systems, Inc.$89
  • Inari Medical, Inc.$70
  • Boston Scientific$40
  • plus $31 from 3 others

What the payments were for

  • Food & beverage$51984%
  • Education$9916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$20,285 in reported general payments places this provider in the 85th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$51,146
Medicare patients
181
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$168,982
Trelegy ElliptaFluticasone/Umeclidin/Vilanter123$131,098
XolairOmalizumab24$81,763
NucalaMepolizumab13$50,010
Incruse ElliptaUmeclidinium Bromide86$47,244
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$34,431
Combivent RespimatIpratropium/Albuterol Sulfate47$32,078
Breo ElliptaFluticasone/Vilanterol49$29,573
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$21,513
Spiriva HandihalerTiotropium Bromide19$21,248
EliquisApixaban18$13,649
Ventolin HfaAlbuterol Sulfate79$6,553
BreynaBudesonide/Formoterol Fumarate18$6,466
SymbicortBudesonide/Formoterol Fumarate17$5,470
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$5,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta, Breo Ellipta$194$292,356329 claims
Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat$15$222,57398 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →